Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer

Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer

Bibliographic Details
Main Authors: Price, T J, Bruhn, M A, Lee, C K, Hardingham, J E, Townsend, A R, Mann, K P, Simes, J, Weickhardt, A, Wrin, J W, Wilson, K, Gebski, V, Van Hazel, G, Robinson, B, Cunningham, D, Tebbutt, N C
Format: Online
Language:English
Published: Nature Publishing Group 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366893/

Similar Items

Similar Items